Eberle Fabian, Lautenschläger Stefan, Engenhart-Cabillic Rita, Jensen Alexandra D, Carl Barbara, Stein Marco, Debus Jürgen, Hauswald Henrik
Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute for Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Cancer Manag Res. 2020 Jan 28;12:633-639. doi: 10.2147/CMAR.S217824. eCollection 2020.
Patients with recurrent glioma after prior radiotherapy have a poor prognosis. Carbon ion beam radiotherapy offers highly conformal dose distributions and more complex biological radiation effects eventually resulting in optimized normal tissue sparing and improved outcome. The aim of this study was to analyze toxicity, local control and overall survival after reirradiation of recurrent high-grade glioma with carbon ion radiotherapy.
Between 10/2015 and 12/2018, 30 patients (median age: 59 years) with recurrent high-grade glioma were reirradiated with carbon ion beams and retrospectively analyzed. Diagnosis of recurrent glioma was based on magnetic resonance imaging. Thirteen patients had repeated resection prior to reirradiation and 24 patients underwent additional chemotherapy. The median initial radiation dose was 60 Gy and the median time interval between the initial and repeated radiotherapy was 10 months. The reirradiation dose was 45 Gy (relative biological effectiveness) applied in 15 fractions. All patients received regular follow-up imaging after reirradiation. Kaplan-Meier estimation, log rank test and Cox regression analysis were used for statistical assessment.
Applying common toxicity criteria, there were no grade 5 or 4 adverse events, while 8 patients showed grade 3 adverse events. The median follow-up after reirradiation was 11 months and the median overall survival after diagnosis of recurrent high-grade glioma was 13 months. The 6-, 12- and 24-month overall survival rates after diagnosis of recurrent high-grade glioma were 76%, 50% and 19%, respectively. Upon multivariate Cox regression analysis, a Ki67 score of the initial tumor histology of less than 20% was prognostic. Repeated resection or chemotherapy for the recurrent disease did not result in significantly prolonged survival.
Carbon ion reirradiation in recurrent high-grade glioma is safe and feasible. No radiation-associated grade 4 toxicities were documented and treatment was tolerated well.
曾接受过放疗的复发性神经胶质瘤患者预后较差。碳离子束放疗可提供高度适形的剂量分布以及更复杂的生物辐射效应,最终实现优化的正常组织保护并改善治疗结果。本研究的目的是分析碳离子放疗复发性高级别神经胶质瘤后的毒性、局部控制情况和总生存期。
在2015年10月至2018年12月期间,对30例(中位年龄:59岁)复发性高级别神经胶质瘤患者进行碳离子束再照射,并进行回顾性分析。复发性神经胶质瘤的诊断基于磁共振成像。13例患者在再照射前进行了重复切除,24例患者接受了额外的化疗。初始放疗的中位剂量为60 Gy,初始放疗与重复放疗之间的中位时间间隔为10个月。再照射剂量为45 Gy(相对生物效应),分15次给予。所有患者在再照射后均接受定期的随访成像。采用Kaplan-Meier估计法、对数秩检验和Cox回归分析进行统计学评估。
应用常见毒性标准,未出现5级或4级不良事件,而8例患者出现3级不良事件。再照射后的中位随访时间为11个月,复发性高级别神经胶质瘤诊断后的中位总生存期为13个月。复发性高级别神经胶质瘤诊断后的6个月、12个月和24个月总生存率分别为76%、50%和19%。多因素Cox回归分析显示,初始肿瘤组织学的Ki67评分低于20%具有预后意义。对复发性疾病进行重复切除或化疗并未显著延长生存期。
碳离子再照射复发性高级别神经胶质瘤是安全可行的。未记录到与放疗相关的4级毒性反应,且治疗耐受性良好。